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ABSTRACT
Hypoxia-inducible factors (HIFs) are critical tran-
scription factors that mediate cell survival during
reduced oxygen conditions (hypoxia). At regular
oxygen conditions (normoxia), HIF-1a and HIF-2a
are continuously synthesized in cells and degraded
via the ubiquitin–proteasome pathway. During
hypoxia, these proteins are stabilized and
translocate to the nucleus to activate transcription
of target genes that enable cell survival at reduced
oxygen levels. HIF proteins are tightly regulated via
post-translational modifications including
phosphorylation, acetylation, prolyl-hydroxylation
and ubiquitination. Here we show for the first time
that exogenous and endogenous HIF-2a are also
regulated via the ubiquitin-like modifier small
ubiquitin-like modifiers (SUMO). Using mutational
analysis, we found that K394, which is situated in
the sumoylation consensus site LKEE, is the major
SUMO acceptor site in HIF-2a. Functionally,
sumoylation reduced the transcriptional activity of
HIF-2a. Similar to HIF-1a, HIF-2a is regulated by
the SUMO protease SENP1. The proteasome inhibi-
tor MG132 strongly stabilized SUMO-2-conjugated
HIF-2a during hypoxia but did not affect the total
level of HIF-2a. The ubiquitin E3 ligases von
Hippel–Lindau and RNF4 control the levels of
sumoylated HIF-2a, indicating that sumoylated
HIF-2a is degraded via SUMO-targeted ubiquitin
ligases.
INTRODUCTION
Many diﬀerent post-translational modiﬁcations including
phosphorylation, acetylation, methylation and glyco-
sylation are involved in regulating the activity of
proteins. Sumoylation, the process of attaching a small
ubiquitin-like modiﬁer (SUMO) protein to a target
protein, is a more recently discovered reversible post-
translational modiﬁcation (1,2). SUMOs are
covalently conjugated to acceptor lysines in sumoylation
consensus motifs (wKx(E/D), where w stands for V, L, I,
M or F and x can be any amino acid) in target proteins.
Sumoylation regulates many diﬀerent cellular processes
such as gene expression, signal transduction,
chromatin structure and the maintenance of the
genome by attachment to and modulation of target
proteins.
Three SUMO family members have been described in
vertebrates, SUMO-1, -2 and -3, encoded by three diﬀer-
ent genes (3). The mature forms of SUMO-2 and SUMO-3
are very similar ( 95% identical) but diﬀer from SUMO-1
( 50% identical) (4). SUMO-1 and SUMO-2 each have a
unique subset of substrates as well as a shared subset to
which both isoforms can be conjugated (5).
Low oxygen concentration leads to adaptive changes in
the transcription of a range of genes. The Hypoxia-
Inducible Factors (HIFs) mediate the transcriptional
activation of genes that allow cells and tissues to cope
with low oxygen conditions (6,7). HIFs are heterodimers,
composed of one a and one b subunit. While the HIF-1b/
ARNT (aryl hydrocarbon receptor nuclear translocator)
subunit is stable, the HIF-a proteins (HIF-1a, HIF-2a and
HIF-3a) are continuously synthesized and degraded under
normoxic conditions. During normoxia, two conserved
proline residues in the oxygen-dependent degradation
domain (ODD) of HIF-a are hydroxylated by HIF-
speciﬁc prolyl hydroxylase-domain proteins (PHD 1, 2
and 3). Hydroxylation of the prolyl residues mediates
binding of the von Hippel–Lindau (VHL) ubiquitin
ligase complex responsible for ubiquitination and degra-
dation of HIF-1a in a proteasome-dependent manner
(8,9). The PHD proteins require molecular oxygen for
their enzymatic activity and no longer function during
hypoxia. Consequently, degradation no longer occurs
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late and translocate to the nucleus (10–12).
HIF-1a and HIF-2a are 48% identical and their stabil-
ity and transcriptional activity are regulated via shared
mechanisms (13,14). Both proteins play important
and similar, but non-redundant roles in fetal development
and tumor angiogenesis. Mouse embryos in which HIF-1a
expression was disrupted exhibited multiple defects in car-
diovascular development and died early during develop-
ment (E11.5) (15). HIF-2a
–/– mice generated by diﬀerent
groups diﬀered somewhat in phenotype, possibly due to
diﬀerences in genetic backgrounds. Phenotypes observed
include defective vascular remodeling with local hemor-
rhage (16), defective fetal catecholamine production (17)
or altered lung maturation secondary to impaired
surfactant secretion by alveolar type 2 cells (18).
The activity of HIF-2a is tightly controlled by
post-translational modiﬁcations including prolyl-
hydroxylation, ubiquitination and phosphorylation. We
have investigated the sumoylation of HIF-2a, which
contains two consensus sumoylation sites, LK394EE and
LK497IE. We have generated HIF-2a mutants in which
these consensus sumoylation sites were disrupted and
demonstrate that K394 is used for SUMO conjugation
and plays a role in the regulation of HIF-2a activity.
Interestingly, SUMO-2-conjugated HIF-2a is rapidly
degraded during hypoxia via SUMO-targeted ubiquitin
ligases.
MATERIALS AND METHODS
Expression vectors
Plasmids containing the human wild-type HIF-1a and -2a
cDNA tagged at the N-terminus with three consecutive
FLAG tags were a kind gift from Dr A. Groot (Utrecht
University, Utrecht, The Netherlands) (19,20). The
5xHREpGL3-Luciferase reporter was a kind gift from
Dr M. Duyndam (VUMC, Amsterdam, The
Netherlands). The FLAG-SUMO-2 lentiviral construct
was generated by inserting his6-SUMO-2 into the
EcoRV site of plasmid pLV-CMV-IRES-eGFP (21). The
FLAG epitope was subsequently introduced in this
plasmid via oligonucleotide insertion into the PstI site.
Plasmids encoding shRNAs were obtained from the
MISSION shRNA Library (Sigma Aldrich): control
shRNA, SHC-002; RNF4 shRNA, TRCN0000017053;
RSUME shRNA, TRCN0000004095; SENP1 shRNA,
TRCN0000004399 and VHL shRNA, TRCN0000010460.
Mutagenesis
The K394R, K497R, E396A and E499A mutations in
HIF-2a were generated by site-directed mutagenesis
using the Quickchange II kit according to the instructions
of the manufacturer (Stratagene). The following
oligonucleotides were used to generate these mutations:
K394R, forward 50-ctattcaccaagctaagggaggagcccgag-30
and reverse 50-ctcgggctcctcccttagcttggtgaatag-30; K497R,
forward 50-gataacgacctgaggattgaagtgattg-30 and reverse
50-caatcacttcaatcctcaggtcgttatc-30; E396A, forward 50-ca
agctaaaggaggcgcccgaggagctg-30 and reverse 50-cagctcctc
gggcgcctcctttagcttg-30; E499A, forward 50-gacctgaa
gattgcagtgattgagaag-30 and reverse 50-cttctcaatcactgcaatc
ttcaggtc-30. All mutants were sequence veriﬁed.
Cell culture, transfection and infection
HeLa cells stably expressing his6-SUMO-1 or his6-
SUMO-2 were previously described (5). The HeLa cell
line stably expressing FLAG-SUMO-2 was generated by
infection with the lentivirus encoding FLAG-SUMO-2.
HeLa cells were grown in Dulbecco’s modiﬁed Eagle
medium (DMEM), supplemented with 10% FCS and
100U/ml penicillin and streptomycin (Invitrogen).
Hypoxic stabilization of HIF-a was performed at 1% O2
for 24h. Transient transfections were performed using
2.5ml Polyethylenimine (PEI, 1mg/ml, Alpha Aesar) per
mg DNA. Trichostatin A (TSA, Sigma Aldrich) was added
to the culture medium at 300nM for 24h where indicated.
MG132 (Sigma Aldrich) was added to the culture medium
at 10mM for 4 or 7h where indicated. For both drugs,
control cells were treated with dimethyl sulphoxide
(DMSO). Cycloheximide was added to the culture
medium at 10mg/ml where indicated. Lentiviral infections
were performed at an MOI of 1 for 24h. Cells were
subsequently incubated for another 48h prior to lysis.
Luciferase assays
Cells were cultured in 24-well plates and cotransfected
with 0.2mg luciferase reporter plasmid and 0.5mg expres-
sion plasmid as indicated. Experiments were carried out in
triplicate and additional wells were prepared for control
immunoblotting experiments. Cells were lysed in Reporter
Lysis Buﬀer (Promega) for luciferase activity measure-
ments or in NuPage LDS protein sample buﬀer
(Invitrogen) for immunoblotting.
Cell ﬁxation and immunostaining
HeLa cells were cultured on glass cover slips in 24-well
plates and transfected with 0.5mg expression plasmid. The
cells were ﬁxed for 20min in 3.7% paraformaldehyde at
room temperature and permeabilized in phosphate-
buﬀered saline (PBS) containing 0.5% Triton X-100 for
10min. Cells were blocked with 10% goat serum for
30min. The cells were incubated with primary antibody
(mouse anti FLAG, 1:1000 in PBS/T, 10% NGS) for 1h,
washed and incubated with secondary antibody (goat anti
mouse-Alexa 488, 1:1000 in PBS/T, 10% NGS) for 1h.
The cells were washed 5  with PBS/T, mounted in
Vectashield, sealed with nail varnish and stored at  20 C.
Microscopy
Microscopy experiments were carried out using a confocal
microscope system (model TCS/SP2, Leica). Images were
acquired with a 100  NA 1.4 plan Apo objective and were
analysed with Leica confocal software.
Antibodies
Peptide antibody AV-SM23-0100 (Eurogentec) against
SUMO-2/3 was described previously (22). Monoclonal
antibody T5326 against g-tubulin, polyclonal antibody
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against FLAG were obtained from Sigma Aldrich.
Polyclonal antibody NB100-122 against HIF-2a was
obtained from Novus Biologicals. Polyclonal antibody
against RNF4 was a kind gift of Dr J. Palvimo.
Secondary antibodies used were anti-rabbit HRP and
anti-mouse HRP (Pierce Chemical Co.). The secondary
antibody used for immunoﬂuorescence was goat anti
mouse Alexa 488 (Invitrogen).
Puriﬁcation of his6-SUMO conjugates
Cells were cultured in 14cm diameter culture dishes and
transfected with 10mg FLAG-HIF-1a or -2a expression
plasmids as indicated. His6-SUMO conjugates were
puriﬁed essentially as previously described (23). Cells
were scraped in ice-cold PBS. Two small aliquots of
each sample were lysed in LDS protein sample buﬀer
(Invitrogen) as input control, or in 8M Urea, 100mM
Na2HPO4/NaH2PO4, 10mM Tris–HCl, pH 7.0 to deter-
mine the protein concentration. The remaining cells were
solubilized in lysis buﬀer (6M Guanidinium-HCl, 100mM
Na2HPO4/NaH2PO4, 10mM Tris–HCl, pH 8.0, 20mM
Imidazole, 10mM b-mercaptoethanol) and sonicated to
reduce the viscosity. His6-SUMO conjugates were
enriched on Ni-NTA Agarose beads (Qiagen) and
washed using wash buﬀers A–D. (Buﬀer A: 6M
Guanidinium–HCl, 100mM NaH2PO4/Na2HPO4,
10mM Tris–HCl pH 8.0 and 0.2% Triton-X-100. Buﬀer
B: 8M Urea, 100mM NaH2PO4/Na2HPO4, 10mM Tris–
HCl pH 8.0 and 0.2% Triton-X-100. Buﬀer C: 8M Urea,
100mM NaH2PO4/Na2HPO4, 10mM Tris–HCl pH 6.3
and 0.2% Triton-X-100. Buﬀer D: 8M Urea, 100mM
NaH2PO4/Na2HPO4, 10mM Tris–HCl pH 6.3 and 0.1%
Triton-X-100). These wash buﬀers also contained 10mM
b-mercaptoethanol. Samples were eluted in 6.4M Urea,
80mM NaH2PO4/Na2HPO4, 8mM Tris–HCl pH 7.0,
200mM imidazole.
Puriﬁcation of FLAG-SUMO conjugates
Cells were grown in 14cm diameter dishes and cultured
for 7h at 1% O2 before lysis. Cell extracts were prepared
in SDS buﬀer [2% SDS, 50mM Tris–HCl, pH 7.5 and
10mM iodoacetamide (23)] and incubated at room tem-
perature for 15min. The viscosity of the samples was
reduced by sonication. SDS concentration of the
samples was reduced by dilution in buﬀer B (50mM
Tris-HCl, pH 7.5, 150mM NaCl, 0.5% NP40 and
0.5mM b-mercaptoethanol). Samples were centrifuged at
9000g for 30min at 4 C and incubated for 3h at 4 C with
Anti-FLAG M2 beads (M8823, Sigma Aldrich). The
beads were collected, washed 5 times with wash buﬀer
(50mM Tris–HCl, pH 7.5, 150mM NaCl and 0.5%
NP40) and eluted with 15ml wash buﬀer containing
100mg/ml FLAG peptide for 15min at 4 C. Supernatant
was collected for immunoblotting.
Immunoblotting
Protein samples were size fractionated on Novex 4–12%
Bis-TRIS gradient gels using 4-morpholineprop-
anesulfonic acid buﬀer (Invitrogen) or on regular
SDS-PAGE gels with a tris-glycine buﬀer. Note that
these diﬀerent methods cause slight diﬀerences in the
running behavior of proteins (Invitrogen). Size
fractionated proteins were subsequently transferred onto
Hybond-C extra membranes (Amersham Biosciences)
using a submarine system (Invitrogen). The membranes
were incubated with speciﬁc antibodies as indicated.
Bound antibodies were detected via chemiluminescence
with ECL Plus (Amersham Biosciences).
RESULTS
HIF-2a contains two conserved consensus
sumoylation sites
The transcription factor HIF-1a is regulated by SUMO
conjugation. As a homologue of HIF-1a, HIF-2a shows
close similarity in sequence, function and regulation.
HIF-1a contains three consensus sumoylation sites, two
of which are involved in the regulation of its
transcriptional activity (6,24–26). Two potential SUMO
acceptor sites matching the consensus sequence are
present in HIF-2a (Figure 1). These sites are conserved
in a wide range of species including Mus musculus,
Rattus norvegicus, Bos taurus, Gallus gallus and Danio
rerio.
To compare SUMO conjugation between HIF-1a and
-2a in cells, we made use of published stable cell lines
expressing his6-SUMO-1 and his6-SUMO-2 (5). HeLa,
HeLa
his6-SUMO-1 and HeLa
his6-SUMO-2 cells were
transfected with plasmids encoding FLAG-HIF-1a,- 2 a
or an empty vector. The cells were placed at 1% O2 24h
post-transfection and cultured for another 24h before
lysis and puriﬁcation of his6-SUMO conjugates.
Expression levels of HIF-1a and -2a were checked in
total cell lysate samples. SUMO-modiﬁed forms of
FLAG-HIF-1a and -2a could be detected in both the
his6-SUMO-1 and his6-SUMO-2 puriﬁed samples
(Figure 1C). Note that unmodiﬁed, but not
SUMO-modiﬁed, FLAG-HIF could be detected in the
HeLa negative control. These results indicate that analo-
gous to HIF-1a, HIF-2a is a substrate for sumoylation.
HIF-2a was found to be conjugated to both SUMO
proteins at least as eﬃciently as HIF-1a.
HIF-2a is sumoylated on K394
To investigate whether the consensus sumoylation sites
present in HIF-2a are used for SUMO conjugation in
cells, we created plasmids encoding mutant forms of
FLAG-HIF-2a lacking one or both SUMO acceptor
lysines. HeLa
his6-SUMO-2 cells were transfected with
plasmids encoding FLAG-HIF-2a wild-type and
mutants and cultured at 1% O2 for 24 hours. His6-
SUMO-2 conjugates were puriﬁed from these cells and
analysed by immunoblotting. At least 2 SUMO-modiﬁed
forms of FLAG-HIF-2a wild-type could be detected
(Figure 2, lane 3) that were absent in the control
samples (lanes 1 and 2). Disrupting the ﬁrst consensus
site by mutating K394 (lane 4) strongly reduced
sumoylation of FLAG-HIF-2a compared to wild-type.
In contrast, disrupting the second consensus site had no
1924 Nucleic Acids Research, 2010, Vol.38, No. 6eﬀect on sumoylation levels (lane 5). A mutant in which
both sites were disrupted did not exhibit a further reduc-
tion in sumoylation compared to the K394R single mutant
(lane 6 compared to 4). These results indicate that lysine
394 is the major SUMO acceptor site of HIF-2a.
To rule out the possibility that our results could be
attributed to potential modiﬁcations of these lysine
residues other than sumoylation, a second set of mutants
was prepared. In these mutants, the consensus
sumoylation sequence was disrupted by mutating the
glutamic acid residues, while leaving the lysines intact.
This second set of mutants was used to repeat this exper-
iment and conﬁrmed our ﬁndings with the lysine to
arginine mutants (Supplementary Figure S1). Mutating
E396 resulted in a similar reduction of sumoylation
compared to the K394R mutant. Disrupting the second
consensus site by mutating E499 had no eﬀect on
sumoylation.
Sumoylation of HIF-2a leads to a reduction
in transcriptional activity
Since sumoylation of transcription factors often leads
to a reduction in their activity (27), we compared the
transcriptional activity of wild-type and mutant
FLAG-HIF-2a using an HRE-luciferase reporter
plasmid (Figure 3). Mutating either K394 or E396
increased the transcriptional activity of HIF-2a while the
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Figure 1. HIF-2a contains two conserved consensus sumoylation sites. (A) Structural domains of HIF-2a. Two consensus sumoylation sites are
present in human HIF-2a,L K 394EE and LK497IE, which are well conserved in other species. (B) Sequence alignment between HIF-1a and HIF-2a.
Both potential HIF-2a sumoylation sites have equivalent sites in HIF-1a, a known SUMO substrate. (C) FLAG-HIF-1a and -2a are conjugated to
SUMO-1 and to SUMO-2. HeLa, HeLa
his6-SUMO-1 and HeLa
his6-SUMO-2 cells were transfected with plasmids encoding FLAG-HIF-1a,- 2 a or an
empty vector control. The cells were grown at 1% O2 for 24h, lysed and his6-SUMO conjugates were puriﬁed. Puriﬁed fractions were separated by
SDS–PAGE, transferred to membranes and probed with an anti-FLAG antibody. Total cell lysates were included as input controls. Several
SUMO-modiﬁed forms of FLAG-HIF-1a and -2a could be detected in the his6-SUMO-2 enriched samples whereas only mono-sumoylated forms
could be detected in the his6-SUMO-1 enriched samples. bHLH, basic helix-loop-helix; PAS, Per/Arnt/Sim domain; ODD, oxygen dependent
degradation domain; N-TAD, N-terminal transactivation domain; C-TAD, C-terminal transactivation domain.
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similar to that of the wild-type (Figure 3A). Neither
double mutant was transcriptionally more active than
HIF-2a proteins carrying only the single K394R or
E396A mutation. Increased transcriptional activity of
the sumoylation-impaired HIF-2a mutants was not due
to an increase in expression of these mutant proteins
(Figure 3B).
Sumoylation does not aﬀect the subcellular
localization of HIF-2a
Sumoylation has previously been shown to alter the
subcellular localization of a subset of target proteins
including RanGAP1 (28,29). To investigate whether
sumoylation has an eﬀect on the subcellular localization
of HIF-2a, cells were transfected with plasmids encoding
wild-type or mutant FLAG-HIF-2a and cultured for 24h
at 1% O2 before ﬁxation. The localization of the
FLAG-HIF-2a proteins was determined using immu-
noﬂuorescence (Figure 4). FLAG-HIF-2a wild-type was
found to be predominantly localized to the nucleoplasm.
Disrupting the major sumoylation consensus site by
mutating K394 or E396 did not inﬂuence the localization
of FLAG-HIF-2a.
SUMO-modiﬁed HIF-2a is degraded by the
ubiquitin–proteasome system
We have previously reported that proteasome inhibition
strongly increases the total pool of SUMO-2/3 conjugates
(30). Moreover, we have identiﬁed a subset of SUMO-2
conjugates that are stabilized by proteasome-inhibition
and veriﬁed that the ubiquitin–proteasome system specif-
ically degraded the SUMO-2-conjugated forms of hnRNP
M, MCM-7 and PIAS-1 without aﬀecting the total pools
of these proteins. To investigate whether sumoylation reg-
ulates HIF-2a stability, we puriﬁed his6-SUMO-2 conju-
gates from HeLa cells that were transfected with plasmids
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Figure 3. SUMO modiﬁcation of HIF-2a on K394 reduces its
transcriptional activity. HeLa cells were cotransfected with wild-type
or mutant forms of FLAG-HIF-2a and an HRE-luciferase reporter
vector (cartoon). Cells were kept normoxic (21% O2) or cultured
hypoxic (1% O2) for 24h before being lysed in Reporter Lysis Buﬀer
(Promega) for luciferase activity measurements. Control cell lysates
were prepared in LDS sample buﬀer and analysed by immunoblotting
to determine the FLAG-HIF-2a expression levels. (A) The
transcriptional activity of wild-type FLAG-HIF-2a was compared to
the mutants. Mutating either the K394 or E396 in the ﬁrst consensus
sumoylation site resulted in an increase in transcriptional activity over
the wild-type both in hypoxic and normoxic samples. Mutations made
in the second sumoylation consensus site had no eﬀect on the
transcriptional activity of FLAG-HIF-2a. The activity of wild-type
HIF-2a under normoxic and under hypoxic conditions was set to 1.
A single representative experiment is shown that was carried out in
triplicate. The experiment was independently repeated twice with
similar results. (B) The expression levels of wild-type and mutant
FLAG-HIF-2a proteins were determined by immunoblotting using an
anti-FLAG antibody, loading was veriﬁed using an anti-g-tubulin
antibody. The increase in transcriptional activity of the
sumoylation-impaired HIF-2a mutants was not due to increased
expression.
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Figure 2. K394 in HIF-2a is a SUMO acceptor site. HeLa and
HeLa
his6-SUMO-2 cells were transfected with plasmids encoding
FLAG-HIF-2a wild-type and the indicated mutant proteins. The cells
were cultured at 1% O2 for 24h and lysed 48h post-transfection.
His6-SUMO-2 conjugates were enriched using metal aﬃnity chromatog-
raphy. Enriched fractions were separated by SDS-PAGE, transferred to
membranes and probed with anti-FLAG or anti-SUMO-2/3 antibody.
Total cell lysates were included as input controls. K394 was found to be
the major SUMO acceptor lysine, whereas K497 appeared not to be
used for SUMO conjugation. Total cell lysates were probed with an
antibody speciﬁc for g-tubulin as a loading control.
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The cells were cultured at 1% O2 in the presence or
absence of the proteasome inhibitor MG132 for 4h
before being lysed. His6-SUMO-2 conjugates were
analysed by immunoblotting. As expected, proteasome
inhibition strongly stabilized SUMO-2 conjugates
(Figure 5A). SUMO-modiﬁed FLAG-HIF-2a exhibited
a very strong accumulation upon proteasome inhibition
by MG132, whereas the stability of unmodiﬁed HIF-2a
was not signiﬁcantly aﬀected. Accumulation of
SUMO-modiﬁed HIF-2a could be strongly reduced by
disrupting the LK394EE sumoylation site but not by dis-
ruption of the LK497IE site. The E to A mutants were used
for this experiment to interfere as little as possible with
potential direct ubiquitination of lysines.
In order to further investigate whether sumoylation has
an eﬀect on the stability of the total pool of HIF-2a,w e
compared the stability of FLAG-HIF-2a wild-type versus
the E396A mutant employing cycloheximide to block
protein synthesis. HeLa cells were transfected with
plasmids encoding wild-type FLAG-HIF-2a or the
E396A mutant. The cells were kept at 21% oxygen and
24h post-transfection cells were cultured for 3 or 5h in the
presence or absence of cycloheximide. Total cell lysates
were prepared and analysed by immunoblotting to
compare total FLAG-HIF-2a levels. Cells treated with
cycloheximide showed greatly reduced levels of
FLAG-HIF-2a compared to control samples
(Figure 5B). No diﬀerences in stability were observed for
the total pools of wild-type and E396A mutant
FLAG-HIF-2a.
Endogenous HIF-2a is sumoylated in cells
Subsequently, we investigated the conjugation of
endogenous HIF-2a to SUMOs by employing a HeLa
cell line stably expressing FLAG-SUMO-2.
HeLa
FLAG-SUMO-2 and control HeLa cells were cultured
in the presence or absence of MG132 at 1 or 21% O2 for
7h before lysis and puriﬁcation of FLAG-SUMO-2 con-
jugates. Several SUMO-modiﬁed forms of endogenous
HIF-2a could speciﬁcally be detected in FLAG-SUMO-
2 puriﬁed samples from hypoxic or MG132-treated
HeLa
FLAG-SUMO-2 cells (Figure 6). A substantial increase
in the amount of SUMO-modiﬁed HIF-2a could be
observed after treating the cells with MG132. We
conclude that endogenous HIF-2a is a target for
SUMO-2 during hypoxia and normoxia.
Sumoylated HIF-2a is regulated by SENP1, RNF4
and VHL
Proteasome inhibition strongly stabilized SUMO-
2-conjugated HIF-2a without aﬀecting the total levels of
HIF-2a (Figures 5 and 6), indicating that HIF-2a might be
controlled by SUMO-targeted ubiquitin ligases. RNF4
has previously been shown to act as a SUMO-targeted
ubiquitin ligase (31), therefore we have performed RNF4
knockdown experiments (Figure 7). RNF4 depletion
resulted in a signiﬁcant accumulation of SUMO-
modiﬁed HIF-2a, consistent with a role for RNF4 as a
SUMO-targeted ubiquitin ligase for HIF-2a.
Previously, the sumoylation of HIF-1a was shown to be
regulated via the SUMO protease SENP1 (25) and via the
SUMO E3 ligase RSUME (32). Cheng et al. (25) also
proposed a role for VHL as a SUMO-targeted ubiquitin
ligase in SUMO-dependent HIF-1a degradation during
hypoxia. We used shRNA interference to reduce the
expression levels of endogenous SENP1, RSUME, and
VHL (Figure 7). Downregulating the expression of VHL
resulted in a signiﬁcant accumulation of SUMO-modiﬁed
HIF-2a, consistent with a role for VHL as a second
SUMO-targeted ubiquitin ligase for HIF-2a.
Furthermore, we observed an increase in the levels of
sumoylated HIF-2a upon SENP1 knockdown, consistent
with a role for this SUMO protease in HIF-2a
desumoylation. SENP1 knockdown did not aﬀect the
control
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Figure 5. Proteasome inhibition results in an accumulation of
SUMO-modiﬁed HIF-2a.( A) HeLa cells were cotransfected with
plasmids encoding his6-SUMO-2 and FLAG-HIF-2a wild-type and
the indicated mutant proteins. The cells were cultured at 1% O2 for
4h in the presence of 10mM MG132 or DMSO control and lysed 48h
post-transfection. His6-SUMO-2 conjugates were enriched using metal
aﬃnity chromatography. Enriched fractions were separated by
SDS-PAGE, transferred to membranes and probed with anti-FLAG
or anti-SUMO-2/3 antibody. Total cell lysates were included as input
controls. Ponceau S staining was performed to verify equal loading.
SUMO-2 conjugates and SUMO-2-modiﬁed forms of FLAG-HIF-2a
were found to be strongly increased upon proteasome inhibition.
Mutation of the major SUMO acceptor site LK394EE reduced
HIF-2a-SUMO accumulation whereas mutating the LK497IE consensus
site had no eﬀect. Proteasome inhibition had only marginal eﬀects on
total FLAG-HIF-2a levels. (B) HeLa cells were transfected with
FLAG-HIF-2a wild-type (wt) or the E396A mutant (EA). The cells
were cultured at 21% O2 and treated with cycloheximide (CHX) for
3 or 5h to inhibit protein synthesis. Equal loading was veriﬁed by
Ponceau S staining. L.C., loading control.
1928 Nucleic Acids Research, 2010, Vol.38, No. 6non-sumoylated pool of HIF-2a but did decrease the total
pool of HIF-1a, consistent with the results published by
Cheng et al. (25) (Figure 7 and Supplementary Figure S2).
The shRNA against RSUME did not lead to a change in
the level of SUMO-modiﬁed HIF-2a. However, we cannot
rule out a role for RSUME in HIF-2a regulation as we
were unable to verify the eﬃciency of the downregulation
of this protein in our experiment.
DISCUSSION
We have shown here that HIF-2a is a target protein for
SUMOs; both endogenous and exogenous HIF-2a were
found to be sumoylated in cells. HIF-2a contains two con-
sensus sumoylation sites, LK394EE and LK497IE, and
mutational analysis showed that K394 is the major
SUMO acceptor site in HIF-2a. The FLAG-HIF-2a
K394R and E396A mutants showed a clear reduction in
sumoylation; however, sumoylation was not totally
absent, indicating the presence of at least one non-
consensus site for SUMO modiﬁcation. Functionally,
sumoylation inhibited the transcriptional activity of
HIF-2a.
Recently, we have shown that SUMO-2 conjugation
aﬀects the stability of a subset of conjugates (30). HIFs
are primarily controlled via stability; they are degraded
during normoxia and stabilized during hypoxia (33).
Interestingly, SUMO-2 conjugation enabled the degrada-
tion of HIF-2a during hypoxia. Since the total pool of
HIF-2a was not aﬀected, SUMO-2 conjugation
appeared to be a requirement for HIF-2a degradation
during hypoxia. This indicated that HIF-2a can be con-
trolled by SUMO-targeted ubiquitin ligases (25,31,34).
RNF4 is an important mammalian SUMO-targeted
ubiquitin ligase that controls the stability of sumoylated
PML, PML-RARa and PEA3 (35–37). Consistently,
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lysed 96h after infection. FLAG-SUMO-2 conjugates were enriched.
Enriched fractions were separated by SDS–PAGE, transferred to mem-
branes and probed with anti-HIF-2a or anti-SUMO-2/3 antibody.
Total cell lysates were included as input controls and used to verify
the knockdown eﬃciencies of RNF4 and SENP1. Ponceau S stained
proteins were included to show equal loading (L.C.). An increase in the
amount of HIF-2a-SUMO-2 conjugates was observed upon knock-
down of RNF4, SENP1 and VHL compared to the control sample.
RSUME knockdown did not aﬀect the levels of HIF-2a-SUMO-2
conjugates.
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Figure 6. Endogenous HIF-2a is conjugated to SUMO-2.
HeLa
FLAG-SUMO-2 and HeLa cells were cultured for 7h at 21%
(norm.) or 1% O2 (hyp.) in the presence or absence of MG132.
FLAG-SUMO-2 conjugates were puriﬁed from cell lysates and
puriﬁed samples were analysed by immunoblotting using an antibody
against HIF-2a. Total cell lysates were included as input controls.
Sumoylated forms of HIF-2a were speciﬁcally detected in the
FLAG-SUMO-2 puriﬁed fractions from hypoxic cells and accumulated
upon proteasome inhibition also in the puriﬁed fractions from the
normoxic cells. The membrane was reprobed to verify SUMO-2/3
levels in the puriﬁed samples. Ponceau S stained protein bands were
used as loading controls (L.C.).
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knockdown. Similarly, VHL is a key regulator of HIF
stability during normoxia and part of an ubiquitin E3
ligase complex (8,9). In addition, Cheng et al. (25) have
previously reported the involvement of VHL in the deg-
radation of sumoylated HIF-1a under hypoxic conditions.
Our results suggest that VHL also controls the stability of
sumoylated HIF-2a during hypoxia since VHL knock-
down strongly increased the amount of
SUMO-2-modiﬁed HIF-2a.
Diﬀerent studies have reported conﬂicting roles for
HIF-1a sumoylation (6,24–26,32). Carbia-Nagashima
et al. (32) and Bae et al. (24) reported that sumoylation
stabilizes and activates HIF-1a whereas Cheng et al. (25)
and Berta et al. (6) reported that sumoylation inhibits
HIF-1a. Cheng et al. (25) showed that in mice deﬁcient
for SENP1, the stabilization of HIF-1a during hypoxia
was reduced, resulting in embryonic lethality due to
severe fetal anemia. We have addressed whether SENP1
and RSUME also regulate HIF-2a activity. Knockdown
of SENP1 increased the amount of HIF-2a-SUMO-2 con-
jugates, whereas knockdown of RSUME did not inﬂuence
HIF-2a sumoylation.
Conjugated SUMOs can also act as a binding site for
repressor proteins such as histone deacetylases (HDACs)
(38,39). It appears that HDACs control HIF-2a since the
HDAC-inhibitor TSA increased the activity of HIF-2a
(Supplementary Figure S3). However, this was not depen-
dent on HIF-2a sumoylation since the E396A mutant was
similarly aﬀected by TSA.
In contrast to the K394R and E396A mutations, the
K497R and E499A mutations did not appear to reduce
sumoylation of HIF-2a. Nevertheless, both sumoylation
consensus sites are well conserved from zebraﬁsh to
human. Three consensus sumoylation sites are present in
HIF-1a and two of these sites are situated in sequences
which show a high degree of homology to sequences sur-
rounding the consensus sites found in HIF-2a (Figure 1).
Interestingly, the K391 sumoylation site in HIF-1a and
the K394 sumoylation site in HIF-2a show a high degree
of sequence similarity and both are used for SUMO con-
jugation. HIF-1a K532 and HIF-2a K497 also lie in
highly similar sequence stretches and are both not used
for SUMO conjugation. The presence of a second
sumoylation site that is well conserved but appears not
to be used for SUMO conjugation is puzzling. The site
could potentially be inaccessible for the SUMO conjuga-
tion machinery. Alternatively, speciﬁc E3 factors might be
required that mediate the conjugation of SUMOs to K497
but are missing in our assay. Furthermore, it is possible
that sumoylation of K497 is restricted to speciﬁc stages of
embryonic development or to speciﬁc cell types. The third
HIF-1a consensus site, K477, has been shown to be used
for SUMO conjugation, but no equivalent site is present in
HIF-2a (6,25).
Rapidly growing cancer cells induce a hypoxic environ-
ment. Survival of these cells in such an environment is
enabled, at least in part, by the HIF system. The HIF
pathway is activated in many solid tumors and is therefore
a major drug target for anti-cancer therapy (40).
Overexpression of HIF-2a has been shown in several
diﬀerent tumor types and signiﬁes an advanced tumor
stage and/or poor patient survival outcome. By inducing
the transcription of target genes, it contributes to
vascularization of these tumors and thus to tumor
growth and malignant behavior (14). Our results indicate
that sumoylation inhibits HIF-2a. Inhibiting HIF-2a
activity is expected to limit the growth rate of solid
tumors. Potentially, stimulating the sumoylation or
inhibiting the desumoylation of HIF-2a in tumors could
be a novel strategy to limit tumor progression.
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